Saladax Biomedical, Inc. Expands Distribution of My5-FU in Europe
Partners with Genoxa of Poland and AB ANALITICA of Italy
BETHLEHEM, Pa., Dec. 16, 2011 /PRNewswire/ -- Saladax Biomedical, Inc., a privately held company developing and commercializing novel diagnostic assays to achieve the promise of personalized medicine for new and existing therapeutics, today announced it has entered into distribution agreements with Genoxa of Puck, Poland and AB ANALITICA of Padua, Italy, for My5-FU™, a test that measures levels of a widely-used anti-cancer drug, 5-fluorouracil (5-FU), in the blood of cancer patients.
"Our new partnership with AB ANALITICA and Genoxa continues the expansion of our marketing and distribution channels in Europe, which will facilitate adoption of 5-FU dose management in these new markets for Saladax," said Adrienne Choma, Esq. , senior vice president and Chief Marketing Officer of Saladax.
Genoxa will be the exclusive provider of My5-FU testing services to oncologists in Poland, enabling them to individualize the dose of 5-FU to optimize therapeutic efficacy and reduce toxicity for their patients. Genoxa is a privately owned clinical reference laboratory focused on providing personalized medicine testing services. "We are pleased to introduce this exciting new technology from Saladax to the Polish oncology community and offer cancer patients better treatment options," commented Artur Wilandt, co-founder and CEO of Genoxa.
In Italy, AB ANALITICA will be the exclusive distributor of My5-FU testing kits to hospital and reference laboratories. Mikkel Johansen , marketing manager for AB ANALITICA, said, "We are delighted with our partnership with Saladax. The addition of My5-FU fits nicely into our current portfolio of diagnostic tests." AB ANALITICA is focused on the development and commercialization of diagnostic tests for human infectious diseases, oncology, genetic diseases, target therapies and pharmacogenetics.
Saladax's first commercially available test for innovative dose management; My5-FU measures levels of 5-fluorouracil (5-FU), a widely used chemotherapy drug used in conjunction with other drugs in first-line therapy for colorectal cancer and other solid tumors. The assay technology enables oncologists to determine the optimal dose of 5-FU for each individual patient, thereby increasing the effectiveness of the drug and lessening the risk of severe toxicity and side effects.
About Saladax Biomedical, Inc.
Saladax Biomedical develops and commercializes novel diagnostic assays to achieve the promise of personalized medicine through dose management and companion diagnostic products for existing and new therapeutics. The Company's dose management technology enables physicians to optimize drug dosing to meet individual patient needs, leading to improved response and quality of life. The Company's 15 MyCare™ dose management assays are comprised of proprietary, automated and cost-effective in vitro diagnostic tests, with a principal focus in oncology. The first MyCare assay available is for one of the most common anticancer drugs, 5-fluorouracil (5-FU). This assay is sold by Saladax in Europe as a CE-marked product and will be distributed in Japan by FALCO biosystems. In the United States and Canada, Myriad Genetic Laboratories, Inc. provides testing for 5-FU dose optimization under the trademark OnDose® through a license to Saladax proprietary technology. Saladax also works with pharmaceutical companies to develop companion diagnostics to provide important clinical information to assist in developing and administering new and existing compounds. For more information, visit www.saladax.com, or follow us on Twitter at https://twitter.com/Saladax.
Saladax Biomedical, Inc.
Adrienne Choma, Esq.
Senior VP & Chief Marketing Officer
SOURCE Saladax Biomedical, Inc.
More by this Source
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.